Tuberculosis Therapeutics Market Worth $2.99 Billion By 2030

Tuberculosis Therapeutics Market Growth & Trends

The global tuberculosis therapeutics market size is expected to reach USD 2.99 billion, expanding at a CAGR of 5.09% from 2023 to 2030, according to a new report by Grand View Research, Inc., The demand for TB therapeutics is attributable to the rising prevalence of tuberculosis. According to the World Health Organization's 2022 Global TB report, an estimated 10.6 million people suffered in 2021, a 4.5% increase from 2020, and has accounted for the death of around 1.6 million people. This high rate of mortality demonstrates an unmet need for cost-effective and efficient drugs in the market.

The burden of drug-resistant tuberculosis (DR-TB) increased by 3% between 2020 and 2021, with 450 000 new cases of rifampicin-resistant tuberculosis in 2021. This is the first time in past few years that an increase in the number of people suffering from TB and DR-TB has been reported. The COVID-19 pandemic in 2021 has disrupted many services, including TB care. However, the impact has been severely seen in the TB response. Moreover, because the current vaccine, known as BCG, is over 100 years old and has limited efficacy in adults, the ability to control transmission is limited. Thus, creating business opportunity for therapeutics.

The rising incidence of multidrug-resistant and extensively drug-resistant tuberculosis has further propelled the demand for providing appropriate therapeutics. In December 2022 , the WHO released an updated consolidated guideline featuring major improvements on the treatment of drug-resistant TB. The guideline summarizes and recommends the use of a novel all-oral 6-month regimen consisting of pretomanid, bedaquiline, moxifloxacin, and linezolid (BPaLM) for treatment of patients suffering from MDR/RR-TB. The BPaLM regimen is expected to shorten the duration and offer better outcome of treatment.

Furthermore, key players are focusing on collaborations and partnerships to develop novel tuberculosis therapeutics and to maintain their competitive position in the market. For instance, in July 2021 , to advance tuberculosis therapeutics a new consortium of 30 partners from 13 countries has officially launched. The project is UNITE4TB and is a 7-year plan with an investment of around USD 198 million with a goal to accelerate and improve therapeutics. Moreover, initiatives such as the Ni-kshay Mitra launched in September 2022, have come up in India intending to eliminate and target tuberculosis by the end of 2025.

 Request a free sample copy or view report summary: Tuberculosis Therapeutics Market Report

Tuberculosis Therapeutics Market Report Highlights

• Active TB segment dominated et in 2022 and is attributable to the increasing prevalence and recurrence of condition

• Second line therapy segment is expected to show fastest growth rate over the forecast period owing to increasing demand and the rising research and development for development of newer second-line therapy drugs

• Oral segment dominated the market in 2022 attributable to the availability of a large number of drugs in form of tablets.

• The COVID-19 pandemic influenced the market adversely attributable to the reduced funding for therapeutics and decline in diagnosis rate of disease.

• MEA held the largest market share in 2022 which can be attributed to the enhanced focus on early diagnosis of the disease and improvement in adoption rate of treatments.

Tuberculosis Therapeutics Market Segmentation

Grand View Research has segmented the global tuberculosis therapeutics market report based on disease type, therapy, route of administration, dosage form, distribution channel, and region:

Tuberculosis Therapeutics Disease Type Outlook (Revenue, USD Million, 2018 - 2030)

• Active TB

• Latent TB

Tuberculosis Therapeutics Therapy Outlook (Revenue, USD Million, 2018 - 2030)

• First-Line Therapy

• Second-Line Therapy

Tuberculosis Therapeutics Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Parenteral

• Others

Tuberculosis Therapeutics Dosage Form Outlook (Revenue, USD Million, 2018 - 2030)

• Tablets

• Capsules

• Injection

• Others

Tuberculosis Therapeutics Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

Tuberculosis Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Spain

  • Italy

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Tuberculosis Therapeutics Market

• AstraZeneca

• Johnson & Johnson Services, Inc.

• Eli Lilly and Company

• Viatris Inc. (Mylan N.V.)

• Teva Pharmaceutical Industries, Ltd.

• Sanofi

• Novartis AG

• Sun Pharmaceutical Industries Ltd.

• Pfizer Inc.